On Thursday, GlaxoSmithKline plc (ADR) (NYSE:GSK)’s shares inclined 0.26% to $42.25.
GlaxoSmithKline (GSK) declared that the U.S. Centers for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) voted for a Category B recommendation for meningococcal group B vaccination, counting BEXSERO® (Meningococcal Group B Vaccine), in individuals aged 16 to 23 (with a preferred age of 16-18). This recommendation means that the decision to vaccinate against meningococcal group B will be made by qualified healthcare professionals, based on individual patient risk assessment. BEXSERO®
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, counting vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, counting respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas.
Sanchez Energy Corp (NYSE:SN)’s shares dropped -1.39% to $9.20.
Sanchez Energy Corp (SN) declared the appointment of Jaime Brito as Senior Vice President of Investor Relations, effective June 15, 2015.
Mr. Brito brings more than 20 years of financial and operating experience in the energy sector. Prior to this appointment, Mr. Brito served in various operational roles at Rosetta Resources Inc. counting Forecasting, Regulatory Affairs, GIS Systems and Supply Chain Administration. He has also served in several investor relation positions while at Mariner Energy, Inc. and Halliburton. Mr. Brito earned Bachelor of Science and Master of Science degrees in Civil and Environmental Engineering from Massachusetts Institute of Technology and a Master of Business Administration from Rice University.
Sanchez Energy Corporation, an independent exploration and production company, focuses on the acquisition, exploration, and development of unconventional oil and natural gas resources in the onshore U.S. Gulf Coast. It has about 226,000 net leasehold acres in the oil and condensate, or black oil and volatile oil, windows of the Eagle Ford Shale in South Texas; and about 69,000 net leasehold acres in the Tuscaloosa Marine Shale in Mississippi and Louisiana.
At the end of Thursday’s trade, Raytheon Company (NYSE:RTN)‘s shares dipped -0.80% to $95.57.
The U.S. Army Contracting Command – Warren awarded Raytheon Company (RTN) the TACOM Planned Service Solutions (TS3) indefinite delivery/indefinite quantity (IDIQ) contract. The five-year multiple-award vehicle has a ceiling value of $634 million.
The agreement covers future work on sensors, fire control systems, active protection systems, and robotics and autonomous systems for a variety of U.S. Army platforms.
This is the first such contract awarded by the Contracting Command to Raytheon Company as a prime contractor. The TS3 contract will be managed in the Raytheon IDIQ Service Center to ensure efficiency and contract optimization by the entire company and its teammates. It is anticipated the majority of the task orders will be performed by Raytheon’s Missile Systems business in Tucson.
Raytheon Company develops integrated products, services, and solutions in the areas of sensing; effects; command, control, communications, and intelligence; mission support; and cyber and information security worldwide. It operates in four segments: Integrated Defense Systems (IDS); Intelligence, Information, and Services (IIS); Missile Systems (MS); and Space and Airborne Systems (SAS). The IDS segment provides integrated air and missile defense; radar solutions; naval combat and ship electronic systems; command, control, communications, computers, and intelligence solutions; and air traffic administration systems.
Agilent Technologies Inc (NYSE:A), ended its Thursday’s trading session with 0.82% gain, and closed at $39.58.
Agilent Technologies Inc. (A) declared two additions to its AdvanceBio product family, designed to provide rapid, reproducible results for scientists in the biopharmaceutical industry.
Agilent introduced the products—the AdvanceBio glycan-mapping workflow and the AdvanceBio oligonucleotide column—at HPLC 2015, an international symposium being held in Geneva, Switzerland, this week.
Agilent Technologies, Inc. provides bio-analytical solutions and services to the life sciences, diagnostics and genomics, chemical analysis, communications, and electronics industries worldwide. The company’s Life Sciences and Diagnostics segment offers liquid chromatography systems, columns, and components; liquid chromatography mass spectrometry systems; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; nucleic acid solutions; nuclear magnetic resonance, magnetic resonance imaging, and X-ray diffraction systems; immunohistochemistry; in situ hybridization; hematoxylin and eosin staining; special staining, DNA mutation detection; genotyping; gene copy number determination; identification of gene rearrangements; DNA methylation and gene expression profiling; next generation sequencing target enrichment; and automated gel electrophoresis-based sample analysis systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.+-
